# Zydus Wellness share price today (Zydus Wellness Ltd, NSE: ZYDUSWELL)

> Zydus Wellness share price today: ₹488.80 at the NSE close on 4 November 2026, up 8.5% in a year. Zydus Wellness (NSE: ZYDUSWELL) is worth ₹15,543 crore, trades at a P/E of 70.2 and has closed between ₹381.20 and ₹598.30 over the past 52 weeks. > Zydus Wellness Ltd's share price has risen faster than its earnings: +8.5% in a year, against −43.1% for earnings per share. ZYDUSWELL · FMCG - Personal Care · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/zydus-wellness-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹488.80 (+8.5% in a year)
- P/E: 70.2× (higher than 93% of the last 11 years)
- Revenue (Jun 2026): ₹1,437 Cr (+66.9% on a year ago)
- Profit (Jun 2026): ₹119 Cr (−7.0% on a year ago)
- Operating margin: 17.0% (−1.0 points on a year ago)
- ROCE: 5%, FY26
- ROIC: 3.9%, against a 12.0% cost of capital: −8.1 points

The main question: the share price moved +8.5% in a year while yearly earnings per share moved −43.1%. The difference came from the market paying a higher multiple. ## What is the Zydus Wellness share price today? Zydus Wellness Ltd's share price was ₹488.80 at the close on 4 November 2026. It has been rising for 28 weeks. That is 1.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹381 and ₹598, and at that close it sat 50% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. Over the last 11 years the share price moved +230% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Zydus Wellness this quarter? 2. Revenue up on a year earlier for 10 quarters in a row In the June 2026 quarter revenue was ₹1,437 crore, +66.9% on a year earlier. Why: Sales rose because the international business including Comfort Click grew and the skin, hair and food brands sold more, even as seasonal brands fell. Next results: check whether Comfort Click's profit and margins improve as its US and Middle East operations grow. From the earnings call on 4 Aug 2026. 3. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row From 18.6% to 19.4% of the company by the September 2026 quarter. ## What are Zydus Wellness' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Zydus Wellness reported revenue of ₹1,437 crore, up 66.9% from ₹861 crore a year earlier, and a profit of ₹119 crore, down 7.0% from ₹128 crore. ### Zydus Wellness results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,437 crore | ₹861 crore | +66.9% |
| Profit | ₹119 crore | ₹128 crore | −7.0% |
| Earnings per share | ₹3.74 | ₹4.02 | −7.0% |
| Operating margin | 17.0% | 18.0% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Zydus Wellness' management discussed these results on a call held on 4 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Zydus Wellness share price history? Zydus Wellness closed at ₹488.80 on 4 November 2026, up 8.5% from ₹450.35 a year earlier (7 November 2025) and up 19.1% over five years. Its highest weekly close since March 2016 was ₹598.30 on 3 July 2026. ### Zydus Wellness share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹462.75 | +5.6% |
| 1 month ago · 1 Oct 2026 | ₹493.25 | −0.9% |
| 6 months ago · 8 May 2026 | ₹517.50 | −5.5% |
| 1 year ago · 7 Nov 2025 | ₹450.35 | +8.5% |
| 3 years ago · 3 Nov 2023 | ₹308.65 | +58.4% |
| 5 years ago · 4 Nov 2021 | ₹410.46 | +19.1% |
| 10 years ago · 4 Nov 2016 | ₹169.11 | +189.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹148.24 | +229.7% |
| Highest weekly close since March 2016, also the 52-week high · 3 Jul 2026 | ₹598.30 | −18.3% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹141.19 | +246.2% |
| 52-week low (weekly close) · 6 Mar 2026 | ₹381.20 | +28.2% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Zydus Wellness? 4 Nov 2026: Zydus Wellness closed at ₹488.80, up 5.6% on the week and down 0.9% on the month. 4 Aug 2026: Zydus Wellness held its results call for April to June 2026. Management guided: International business to maintain double-digit growth in upcoming quarters. ### Earlier

- 17 Jul 2026: ex-date for a dividend of ₹1.20 a share. - Results for April to June 2026: Revenue up 66.9% and profit down 7.0% on a year earlier. - 18 Sep 2025: Share split: face value cut from ₹10 to ₹2 a share (ex-date). ## What dividend does Zydus Wellness pay? Zydus Wellness paid ₹1.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.25% at the ₹488.80 close on 4 November 2026. The last was a dividend of ₹1.20 a share, ex-date 17 July 2026. ### Zydus Wellness dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 17 Jul 2026 | ₹1.20 | Dividend | same day |
| 11 Jul 2025 | ₹6 | Dividend | same day |
| 19 Jul 2024 | ₹5 | Dividend | same day |
| 21 Jul 2023 | ₹5 | Dividend | same day |
| 14 Jul 2022 | ₹5 | Dividend | 15 Jul 2022 |
| 14 Jul 2021 | ₹5 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Zydus Wellness Ltd paid out 19% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Zydus Wellness management say on the latest results call? On the call for April to June 2026, held on 4 August 2026, Zydus Wellness' management guided: International business to maintain double-digit growth in upcoming quarters. > “With the business becoming less dependent on the summer season, our diversified portfolio continues to support more balanced growth throughout the year. - Tarun Arora”
> CEO, on the call for April to June 2026

### What management guided

- FY27 effective tax rate at 25% including deferred tax, with 12-15% cash component; FY28 expected at 25% entirely in cash. - Finance cost to hover around current level in upcoming quarters, subject to the euro benchmark rate. - Comfort Click operating profit, profit before tax and net margin expected to improve if current momentum continues. - Seasonal brand growth momentum to return through the remaining FY27, with a more positive performance expected. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/3675/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 4 August 2026.)

## What to watch in Zydus Wellness' next results? When Zydus Wellness reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Seasonal brands: test whether returning growth momentum becomes sustained after rain disruption and retailer inventory pressure. - What to check (from the call)
- Seasonal brands: test whether returning growth momentum becomes sustained after rain disruption and retailer inventory pressure. - Comfort Click: check operating profit, profit before tax and net margin improvement as US and Middle East operations scale. - Finance cost: verify stability around the current level and sensitivity to euro benchmark movement. - Max Protein: monitor offline distribution traction in newer towns alongside continued value, volume and margin growth. ## Which stock lists is Zydus Wellness on? Zydus Wellness is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 434](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Zydus Wellness profitable? Zydus Wellness Ltd earned ₹119 Cr of net profit in the Jun 2026 quarter, −7.0% on the same quarter a year earlier. Full-year FY26 profit was ₹197 Cr. Over 10 years profit has grown 6.5% a year on average. That is 8.3% of the quarter's revenue. The same quarter a year earlier earned ₹128 Cr. 2 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹197 Cr (−43.2% on the year before). Why profit moved: revenue changed +66.9% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −283.0% and revenue +67.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Zydus Wellness make, and is it growing? Zydus Wellness Ltd reported ₹1,437 Cr of revenue in the Jun 2026 quarter, +66.9% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 25.9% a year on average. The last full year, FY26, came in at ₹3,961 Cr. The last four reported quarters add to ₹4,537 Cr. FY26 revenue was ₹3,961 Cr, +46.2% on the year before. Recent pace: the last four quarters grew +67.6% on average, against 25.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +66.3%, against +35.6% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −42.5%, against −21.4% a year (rolling over). ## How much of every ₹100 of sales does Zydus Wellness keep? Zydus Wellness Ltd's operating margin was 17.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 13.0% and 24.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.3 percentage points on the year while gross margin changed +10.7 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Zydus Wellness' profit turning into cash? Over the last 3 years, 105% of Zydus Wellness Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹226 Cr of operating cash against ₹197 Cr of profit. After ₹3,626 Cr of spending on assets, free cash was −₹3,400 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 105% of profit came in as cash: the cash cycle got 119 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 20.5× depreciation over three years. The next section checks what that spending is building. ## Where does Zydus Wellness' cash go? Zydus Wellness Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 106 days in FY26, up from −13 days in FY21. It spent ₹4,073 Cr on assets over the last 3 years. Customers take 35 days to pay, and stock sits for 178 days on average. At FY26 sales of ₹3,961 Cr, each day of that cycle ties up about ₹10.9 Cr, so roughly ₹1,150 Cr is tied up in the business at any time. FY26: customers took 35 days to pay and stock sat for 178 days, about 5.9 months of sales sitting as stock, for a full cycle of 106 days, longer than FY21's −13. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 178 days. Customers pay about 35 days after that. Suppliers are paid at 107 days. Together that makes the 106-day cycle. Spending on assets: ₹4,073 Cr over the last 3 years, against ₹199 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹23.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Zydus Wellness' P/E ratio, and how does it compare with its own history? Zydus Wellness Ltd's P/E is 70.2×, near the high end of its own history: higher than 93% of past readings. Its usual P/E (the middle reading) is 37.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹5.92. Why the multiple is where it is: over the past year earnings per share moved −43.1% while the price moved +8.5%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +3.6% a year; about −7.2% a year came from earnings growth and about +10.8 percentage points from the multiple (the market paying more); over 10 years the price moved +11.2% a year; about +2.2% a year came from earnings growth and about +9.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Zydus Wellness business getting better or worse? Zydus Wellness Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −42.5% in the latest quarter, against +30.5% at its best in 12 quarters, with ROCE steady at 4.8%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Zydus Wellness earn on its capital? Zydus Wellness Ltd earned a ROCE of 5% in FY26. Its return on capital used (ROIC) is 8.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.0% net margin and 0.39× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.0% net margin × 0.39× asset turnover × 1.75× leverage (assets divided by equity) ≈ 3.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.9% − 12.0% = −8.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Zydus Wellness have too much debt? Zydus Wellness Ltd has total debt of ₹3,203 Cr against shareholder equity of ₹5,826 Cr as of Jun 2026, so its debt is 0.55× its equity. Year by year, that ratio went from 0.08 in FY22 to 0.55 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Zydus Wellness shareholding pattern? Domestic institutions cut their stake in Zydus Wellness Ltd by 1.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 19.4% of the company. Foreign institutions moved +0.2 points over the same period, to 3.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −1.0 points over 8 quarters, to 19.4%; Foreign institutions: +0.2 points over 8 quarters, to 3.6%; Promoters: +0.0 points over 8 quarters, to 69.6%. Why the owners changed: domestic institutions drove it (−1.0 points). They reduced their stake. ## How far is Zydus Wellness from balance-sheet trouble? For Zydus Wellness Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Zydus Wellness rank in its industry? 39.2 out of 100, rank 9 of 12 in FMCG - Personal Care, with 96% of the evidence available. Zydus Wellness Ltd scores 39.2 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.8 + 7.7 + 6 + 12.7 = 39.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Zydus Wellness compared with? Zydus Wellness ranks 9 of 12 FMCG - Personal Care companies on the 4-Factor Sector Score, with 39.2 out of 100. 1. [Bajaj Consumer Care Ltd](https://www.sectoralpha.in/stocks/bajaj-consumer-care-ltd) BAJAJCON · quiet · Most evidence points up · 100% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.7/35 · Revenue 28% · Profit 84.6% · Operating margin change 7 points · 100% evidence Capital efficiency 19.0/25 · ROCE 30% · Operating margin 25% · 100% evidence Valuation 11.7/20 · P/E 19.3× · PEG 1.64 · 100% evidence Relative strength 6.5/20 · Lead over its industry 0.2% · Lead over NIFTY 500 -10.2% · 1 year 33.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 32.7 + 19 + 11.7 + 6.5 = 69.9 · What this means: Earnings are strong; relative strength in its sector is 0.2% and the one-year return is 33.5%. 2. [Hindustan Unilever Ltd](https://www.sectoralpha.in/stocks/hindustan-unilever-ltd) HINDUNILVR · basing · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.4/35 · Revenue 9.5% · Profit 38% · Operating margin change -2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 28.4% · Operating margin 22% · 100% evidence Valuation 17.2/20 · P/E 39.1× · PEG 0.72 · 100% evidence Relative strength 12.8/20 · Lead over its industry 1% · Lead over NIFTY 500 -9.9% · 1 year -21% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.4 + 15.8 + 17.2 + 12.8 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Marico Ltd](https://www.sectoralpha.in/stocks/marico-ltd) MARICO · quiet · Most evidence points up · 78% evidence 66.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 25.1% · Profit 15% · Operating margin change 1 points · 83% evidence Capital efficiency 17.9/25 · ROCE 47% · Operating margin 21% · 76% evidence Valuation 6.8/20 · P/E 55.1× · PEG n/a · 50% evidence Relative strength 17.4/20 · Lead over its industry 18.9% · Lead over NIFTY 500 6.5% · 1 year 11.2% · 100% evidence · 1 of 12 weeks ahead Exact sum: 24.4 + 17.9 + 6.8 + 17.4 = 66.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) GILLETTE · turning · Evidence leans up · 81% evidence 64.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 8% · Profit 18.4% · Operating margin change -1 points · 88% evidence Capital efficiency 18.1/25 · ROCE 90.7% · Operating margin 29% · 100% evidence Valuation 13.6/20 · P/E 34.5× · PEG 1.7 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -5.5% · 1 year -21.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 23 + 18.1 + 13.6 + 10.1 = 64.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Procter & Gamble Hygiene and Health Care Ltd](https://www.sectoralpha.in/stocks/procter-gamble-hygiene-and-health-care-ltd) PGHH · basing · Evidence leans up · 81% evidence 52.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue -1.6% · Profit -4.7% · Operating margin change -9 points · 88% evidence Capital efficiency 17.6/25 · ROCE 157% · Operating margin 19% · 100% evidence Valuation 13.3/20 · P/E 28.1× · PEG 1.77 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -27.7% · 1 year -48.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.9 + 17.6 + 13.3 + 7.5 = 52.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 6. [Dabur India Ltd](https://www.sectoralpha.in/stocks/dabur-india-ltd) DABUR · basing · Evidence leans up · 81% evidence 51.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.2/35 · Revenue 7.4% · Profit 10.9% · Operating margin change 0 points · 88% evidence Capital efficiency 15.8/25 · ROCE 20.3% · Operating margin 20% · 100% evidence Valuation 9.1/20 · P/E 32.7× · PEG 5.04 · 100% evidence Relative strength 8.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -14.7% · 1 year -25% · 25% evidence · 0 of 12 weeks ahead Exact sum: 18.2 + 15.8 + 9.1 + 8.8 = 51.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Colgate-Palmolive (India) Ltd](https://www.sectoralpha.in/stocks/colgate-palmolive-indialtd) COLPAL · quiet · Evidence leans up · 85% evidence 50.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 8.7% · Profit 2.6% · Operating margin change -3 points · 100% evidence Capital efficiency 21.4/25 · ROCE 108% · Operating margin 28% · 100% evidence Valuation 8.4/20 · P/E 31.4× · PEG 6.07 · 100% evidence Relative strength 8.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.1% · 1 year -28.8% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12.5 + 21.4 + 8.4 + 8.5 = 50.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) EMAMILTD · basing · Evidence leans down · 96% evidence 43.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.0/35 · Revenue 2.8% · Profit -8.2% · Operating margin change -1 points · 88% evidence Capital efficiency 15.1/25 · ROCE 28.1% · Operating margin 22% · 100% evidence Valuation 8.9/20 · P/E 20.7× · PEG 2.99 · 100% evidence Relative strength 10.1/20 · Lead over its industry -3.2% · Lead over NIFTY 500 -13.6% · 1 year -32.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9 + 15.1 + 8.9 + 10.1 = 43.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Zydus Wellness Ltd this page ZYDUSWELL · quiet · Evidence leans down · 96% evidence 39.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.8/35 · Revenue 66.3% · Profit -42.5% · Operating margin change -1 points · 88% evidence Capital efficiency 7.7/25 · ROCE 4.9% · Operating margin 17% · 100% evidence Valuation 6.0/20 · P/E 66.5× · PEG 1.75 · 100% evidence Relative strength 12.7/20 · Lead over its industry 12.9% · Lead over NIFTY 500 1.1% · 1 year -2.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 12.8 + 7.7 + 6 + 12.7 = 39.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Godrej Consumer Products Ltd](https://www.sectoralpha.in/stocks/godrej-consumer-products-ltd) GODREJCP · quiet · Evidence leans down · 100% evidence 35.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 12.9% · Profit 8.6% · Operating margin change -1 points · 100% evidence Capital efficiency 10.3/25 · ROCE 18.8% · Operating margin 19% · 100% evidence Valuation 4.3/20 · P/E 39.4× · PEG 7.49 · 100% evidence Relative strength 2.9/20 · Lead over its industry -8.6% · Lead over NIFTY 500 -18.5% · 1 year -26.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.1 + 10.3 + 4.3 + 2.9 = 35.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jyothy Labs Ltd](https://www.sectoralpha.in/stocks/jyothy-labs-ltd) JYOTHYLAB · quiet · Most evidence points down · 96% evidence 34.0 out of 100 Growth Capital Valuation Relative
12. [Polo Queen Industrial and Fintech Ltd](https://www.sectoralpha.in/stocks/polo-queen-industrial-and-fintech-ltd) PQIF · Too little evidence to rank firmly · 33% evidence 39.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [FMCG - Personal Care](https://www.sectoralpha.in/sectors/fmcg-personal-care), all 12 compared on one page. ## Which companies are close to Zydus Wellness in size? Zydus Wellness is the 9th largest of 12 FMCG - Personal Care companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Gillette India, Procter & Gamble Hygiene and Health Care and Emami. Just below it: Jyothy Labs, Bajaj Consumer Care and Polo Queen Industrial and Fintech. ### FMCG - Personal Care companies close in size

1. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) ₹23,064 crore
2. [Procter & Gamble Hygiene and Health Care Ltd](https://www.sectoralpha.in/stocks/procter-gamble-hygiene-and-health-care-ltd) ₹22,239 crore
3. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) ₹15,703 crore
4. Zydus Wellness Ltd ₹14,723 crore
5. [Jyothy Labs Ltd](https://www.sectoralpha.in/stocks/jyothy-labs-ltd) ₹6,313 crore
6. [Bajaj Consumer Care Ltd](https://www.sectoralpha.in/stocks/bajaj-consumer-care-ltd) ₹4,835 crore
7. [Polo Queen Industrial and Fintech Ltd](https://www.sectoralpha.in/stocks/polo-queen-industrial-and-fintech-ltd) ₹638 crore

[All 12 FMCG - Personal Care companies, largest first](https://www.sectoralpha.in/sectors/fmcg-personal-care#all-companies)

### Companies close in size in other industries

1. [Atul Ltd](https://www.sectoralpha.in/stocks/atul-ltd) ₹14,805 crore · Dyes & Pigments
2. [IFCI Ltd](https://www.sectoralpha.in/stocks/ifci-ltd) ₹14,730 crore · Finance - PSU Lending
3. Zydus Wellness Ltd ₹14,723 crore
4. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore · Pharma - API & CRAMS
5. [KFin Technologies Ltd](https://www.sectoralpha.in/stocks/kfin-technologies-ltd) ₹14,710 crore · Finance - Capital Markets - RTA

## What else do people ask about Zydus Wellness? ### What is Zydus Wellness's share price today? Zydus Wellness Ltd's share price is ₹488.80, +8.5% over the past year. The whole company is worth ₹15,543 Cr on the market. In the last 52 weeks it traded between ₹381 to ₹598; today it is 50% of the way up from the low, 1.6% below its 200-day average (as of 4 November 2026). ### What were Zydus Wellness's latest quarterly results? Zydus Wellness Ltd reported revenue of ₹1,437 Cr and net profit of ₹119 Cr for the Jun 2026 quarter. Revenue rose 66.9% and profit fell 7.0% compared with a year earlier. Earnings per share were ₹3.74. The operating margin was 17.0%, 1.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Zydus Wellness's market cap? Zydus Wellness Ltd's market capitalisation is ₹15,543 Cr at a share price of ₹488.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Zydus Wellness performing? Zydus Wellness Ltd's share price has been rising for 28 weeks. In its latest quarter, revenue rose 66.9% and profit fell 7.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 7 weeks running (as of 4 November 2026). ### Will Zydus Wellness's share price go up? This page does not forecast Zydus Wellness Ltd's share price. What it shows instead: the share price is ₹488.80, and it has been rising for 28 weeks. Its P/E of 70.2× is higher than 93% of its own last 11 years (as of 4 November 2026). ### Where is Zydus Wellness in its business cycle? Zydus Wellness Ltd's FY26 operating margin was 13.0%, against a 13-year range of 13.0% to 24.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 17.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Zydus Wellness story? The main question: the share price moved +8.5% in a year while yearly earnings per share moved −43.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Zydus Wellness a stock worth studying right now? What the numbers show: Zydus Wellness Ltd's share price has risen faster than its earnings: +8.5% in a year, against −43.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Zydus Wellness share price forecast for 2026? What management itself guided: International business to maintain double-digit growth in upcoming quarters. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.